Overview

The Efficacy and Safety of Pomalidomide and Bendamustine With Dexamethasone in Relapsed or Refractory Multiple Myeloma

Status:
Not yet recruiting
Trial end date:
2023-02-01
Target enrollment:
Participant gender:
Summary
To explore the efficacy and safety of pomalidomide and bendamustine with dexamethasone in relapsed or refractory multiple myeloma
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Sun Yat-sen University
Treatments:
BB 1101
Bendamustine Hydrochloride
Dexamethasone
Dexamethasone acetate
Pomalidomide
Thalidomide